Thermo Fisher Scientific vs WuXi AppTec: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Thermo Fisher Scientific Inc (TMO)

Q3 202623 Jul – 15 Sep 2026

▲4

Thermo Fisher Q2 Beat, Raised Guidance, and New Product Launches Drive Stock Up 8.7%

Q2 Earnings Beat and Raised Guidance Thermo Fisher reported Q2 revenue up 10% to $11.99 billion and adjusted EPS of $6.03, beating expectations. Management raised full-year guidance to $47.4–48.1 billion, boosting investor confidence.
This is the primary new financial event that directly drove the stock price higher.
Analyst Target Hikes and Stock Surge Following the strong earnings, analysts at Jefferies and RBC raised their price targets to $630 and $580, respectively. Shares jumped 8.7% to $572.32 as a result.
This shows the direct market reaction and validation from analysts, which is new information.
New Product and Partnership Developments Thermo Fisher received FDA 510(k) clearance for its EXENT myeloma test, partnered with ImmuPharma for manufacturing, and took a minority stake in Mayo Clinic's Precure venture, expanding its clinical and manufacturing reach.
These are new strategic moves that support future growth and were not reported in the previous period.
Broad Demand Recovery and Competitive Gains Thermo Fisher saw a broad demand recovery, outpacing competitor Danaher, with its Analytical Instruments unit returning to growth. This indicates strengthening market position and durable recurring revenue.
This highlights the underlying business momentum that drove the stock and is new to this period.

August 202626 Jul – 15 Sep 2026

▲4

Thermo Fisher's Life-Sciences Recovery Gains Steam as New Deals and Clearances Build

Q2 beat and raised guidance Thermo Fisher reported 10% revenue growth to $11.99 billion and 13% EPS growth, then raised full-year revenue guidance to $47.4–$48.1 billion. Analysts lifted price targets, with RBC going to $580 from $490. Strong results and a brighter outlook push the stock up because investors pay more for faster, more reliable profit growth.
This is the core new event that reset expectations for the company's earnings power.
Broad demand recovery, outpacing Danaher Organic revenue rose 5% and management pointed to improving customer activity across pharma and biotech, while the Analytical Instruments unit returned to growth after two weak years. Rival Danaher cut its growth outlook, so Thermo Fisher looks like a share gainer. A recovering end-market lifts the stock because it suggests the slump in life-sciences spending is ending.
It shows the demand recovery is real and Thermo Fisher is winning relative to a key competitor.
FDA clearance for EXENT myeloma test Thermo Fisher won FDA 510(k) clearance for its EXENT automated mass-spectrometry platform for multiple myeloma, strengthening its specialty cancer diagnostics. New approved products open fresh revenue streams and support higher-margin recurring sales, which investors view as a durable positive for the stock.
A new regulatory approval expands the product portfolio and future revenue.
Mayo Clinic Precure venture Thermo Fisher became a minority owner in Precure, LLC, a Mayo Clinic-led venture building molecular data from one million biospecimens, contributing its Olink proteomics platform, Orbitrap mass spectrometers, kits and reagents. The deal creates a large new outlet for its products and validates its technology, supporting the stock.
A new partnership provides a visible long-term demand channel for Thermo Fisher's instruments and reagents.

Latest26 Jul – 15 Sep 2026

▲4

Thermo Fisher's Life-Sciences Recovery Gains Steam as New Deals and Clearances Build

Q2 beat and raised guidance Thermo Fisher reported 10% revenue growth to $11.99 billion and 13% EPS growth, then raised full-year revenue guidance to $47.4–$48.1 billion. Analysts lifted price targets, with RBC going to $580 from $490. Strong results and a brighter outlook push the stock up because investors pay more for faster, more reliable profit growth.
This is the core new event that reset expectations for the company's earnings power.
Broad demand recovery, outpacing Danaher Organic revenue rose 5% and management pointed to improving customer activity across pharma and biotech, while the Analytical Instruments unit returned to growth after two weak years. Rival Danaher cut its growth outlook, so Thermo Fisher looks like a share gainer. A recovering end-market lifts the stock because it suggests the slump in life-sciences spending is ending.
It shows the demand recovery is real and Thermo Fisher is winning relative to a key competitor.
FDA clearance for EXENT myeloma test Thermo Fisher won FDA 510(k) clearance for its EXENT automated mass-spectrometry platform for multiple myeloma, strengthening its specialty cancer diagnostics. New approved products open fresh revenue streams and support higher-margin recurring sales, which investors view as a durable positive for the stock.
A new regulatory approval expands the product portfolio and future revenue.
Mayo Clinic Precure venture Thermo Fisher became a minority owner in Precure, LLC, a Mayo Clinic-led venture building molecular data from one million biospecimens, contributing its Olink proteomics platform, Orbitrap mass spectrometers, kits and reagents. The deal creates a large new outlet for its products and validates its technology, supporting the stock.
A new partnership provides a visible long-term demand channel for Thermo Fisher's instruments and reagents.

July 202623 Jul – 24 Jul 2026

▲3

Thermo Fisher Q2 Beat and Raised Guidance Drive Stock Higher

Q2 earnings beat and raised full-year guidance Thermo Fisher reported Q2 revenue up 10.5% to $11.99 billion and adjusted EPS of $6.03, beating expectations. Management raised full-year revenue and EPS guidance, signaling confidence in continued momentum. This directly boosts the stock as it shows the company is growing faster than expected and expects that to continue.
This is the core new event that answers why the stock is moving now.
Stock jumps 8.7% on earnings and analyst upgrades Shares climbed 8.7% to $572.32 after the earnings report, and three analysts raised their price targets, with Jefferies going to $630. Upgrades from Wall Street often pull in more buyers, pushing the price higher in the short term and reflecting improved sentiment.
This shows the immediate market reaction and analyst validation, which are key to the price move.
New manufacturing partnership with ImmuPharma Thermo Fisher was selected by ImmuPharma to make its diabetes treatment Kapiglucagon. This adds a new project to Thermo Fisher's drug manufacturing services, bringing in potential future revenue and showing that its services are in demand. It supports the stock by expanding its business.
This is a new contract that adds to the growth story and supports the positive outlook.

23 Jul – 24 Jul 2026

▲3

Thermo Fisher Q2 Beat and Raised Guidance Drive Stock Higher

Q2 earnings beat and raised full-year guidance Thermo Fisher reported Q2 revenue up 10.5% to $11.99 billion and adjusted EPS of $6.03, beating expectations. Management raised full-year revenue and EPS guidance, signaling confidence in continued momentum. This directly boosts the stock as it shows the company is growing faster than expected and expects that to continue.
This is the core new event that answers why the stock is moving now.
Stock jumps 8.7% on earnings and analyst upgrades Shares climbed 8.7% to $572.32 after the earnings report, and three analysts raised their price targets, with Jefferies going to $630. Upgrades from Wall Street often pull in more buyers, pushing the price higher in the short term and reflecting improved sentiment.
This shows the immediate market reaction and analyst validation, which are key to the price move.
New manufacturing partnership with ImmuPharma Thermo Fisher was selected by ImmuPharma to make its diabetes treatment Kapiglucagon. This adds a new project to Thermo Fisher's drug manufacturing services, bringing in potential future revenue and showing that its services are in demand. It supports the stock by expanding its business.
This is a new contract that adds to the growth story and supports the positive outlook.

Q2 202622 Jun – 7 Jul 2026

▲3▼1

Thermo Fisher expands AI, manufacturing, and clinical reach; Q1 stock drop lingers

AI and manufacturing expansions at BIO 2026 Thermo Fisher unveiled AI partnerships with NVIDIA and OpenAI, new manufacturing capacity, and clinical trial expansions. These moves position the company for future growth in high-demand areas, supporting the stock price by showing innovation and capacity to capture more business.
This is a major new strategic push that could drive future revenue and investor optimism.
Drug discovery market growth A new report projects the drug discovery technologies market to grow 11% annually to $51.5 billion by 2030, with AI-based discovery growing fastest. As a key player, Thermo Fisher is well-placed to benefit from this rising demand, which supports its stock price.
It highlights a favorable industry trend that directly benefits TMO's core business.
Q1 revenue beat but stock fell 5.2% Thermo Fisher reported Q1 revenue up 6.2% and beat estimates, but the stock dropped 5.2% after the report. This suggests investors had even higher expectations or concerns about future growth, creating a negative overhang on the shares.
It explains a recent negative price reaction that may still affect investor sentiment.
New CDMO and clinical collaborations Thermo Fisher became the exclusive CDMO for AustinPx's KinetiSol technology and partnered with Arcturus for Phase 3 manufacturing of a cystic fibrosis therapy. These deals expand its service offerings and add potential revenue streams, supporting the stock.
These are concrete new business wins that can drive revenue and show competitive strength.

June 202622 Jun – 7 Jul 2026

▲3▼1

Thermo Fisher expands AI, manufacturing, and clinical reach; Q1 stock drop lingers

AI and manufacturing expansions at BIO 2026 Thermo Fisher unveiled AI partnerships with NVIDIA and OpenAI, new manufacturing capacity, and clinical trial expansions. These moves position the company for future growth in high-demand areas, supporting the stock price by showing innovation and capacity to capture more business.
This is a major new strategic push that could drive future revenue and investor optimism.
Drug discovery market growth A new report projects the drug discovery technologies market to grow 11% annually to $51.5 billion by 2030, with AI-based discovery growing fastest. As a key player, Thermo Fisher is well-placed to benefit from this rising demand, which supports its stock price.
It highlights a favorable industry trend that directly benefits TMO's core business.
Q1 revenue beat but stock fell 5.2% Thermo Fisher reported Q1 revenue up 6.2% and beat estimates, but the stock dropped 5.2% after the report. This suggests investors had even higher expectations or concerns about future growth, creating a negative overhang on the shares.
It explains a recent negative price reaction that may still affect investor sentiment.
New CDMO and clinical collaborations Thermo Fisher became the exclusive CDMO for AustinPx's KinetiSol technology and partnered with Arcturus for Phase 3 manufacturing of a cystic fibrosis therapy. These deals expand its service offerings and add potential revenue streams, supporting the stock.
These are concrete new business wins that can drive revenue and show competitive strength.

22 Jun – 7 Jul 2026

▲3▼1

Thermo Fisher expands AI, manufacturing, and clinical reach; Q1 stock drop lingers

AI and manufacturing expansions at BIO 2026 Thermo Fisher unveiled AI partnerships with NVIDIA and OpenAI, new manufacturing capacity, and clinical trial expansions. These moves position the company for future growth in high-demand areas, supporting the stock price by showing innovation and capacity to capture more business.
This is a major new strategic push that could drive future revenue and investor optimism.
Drug discovery market growth A new report projects the drug discovery technologies market to grow 11% annually to $51.5 billion by 2030, with AI-based discovery growing fastest. As a key player, Thermo Fisher is well-placed to benefit from this rising demand, which supports its stock price.
It highlights a favorable industry trend that directly benefits TMO's core business.
Q1 revenue beat but stock fell 5.2% Thermo Fisher reported Q1 revenue up 6.2% and beat estimates, but the stock dropped 5.2% after the report. This suggests investors had even higher expectations or concerns about future growth, creating a negative overhang on the shares.
It explains a recent negative price reaction that may still affect investor sentiment.
New CDMO and clinical collaborations Thermo Fisher became the exclusive CDMO for AustinPx's KinetiSol technology and partnered with Arcturus for Phase 3 manufacturing of a cystic fibrosis therapy. These deals expand its service offerings and add potential revenue streams, supporting the stock.
These are concrete new business wins that can drive revenue and show competitive strength.

WuXi AppTec Co Ltd (603259.CG)

Q3 202624 Jun – 13 Aug 2026

▲3▼1

WuXi AppTec Surges on Blowout H1 Results, Court Win

Blowout H1 2026 earnings WuXi AppTec reported H1 2026 revenue up 38.9% to 28.9bn yuan and net profit up 29.4% to 11.08bn yuan, topping 10bn for the first time. The company raised full-year guidance, and the stock hit its daily limit.
This is the primary new event that drove the stock higher in July.
Strong backlog and CRDMO model A backlog of 66.43bn yuan, up 25.2%, signals future revenue growth. The CRDMO model, which integrates research, development, and manufacturing, continues to underpin the company's competitive advantage.
This supports the growth narrative and investor confidence.
US court blocks Pentagon label A US court injunction blocked the Pentagon's 'Chinese military company' designation, easing client fears about doing business with WuXi. This removes a key overhang on the stock.
This regulatory relief is a new positive catalyst for the stock.
Selloff and legal uncertainty A mid-July selloff saw CRO stocks limit-down and WuXi fall over 6%, showing sensitivity to market sentiment. The injunction is only preliminary; the lawsuit continues, and an adverse final ruling could still damage its US business.
This highlights the real counterweight and risks that remain.

July 202624 Jun – 13 Aug 2026

▲3▼1

WuXi AppTec Surges on Blowout H1 Results, Court Win

Blowout H1 2026 earnings WuXi AppTec reported H1 2026 revenue up 38.9% to 28.9bn yuan and net profit up 29.4% to 11.08bn yuan, topping 10bn for the first time. The company raised full-year guidance, and the stock hit its daily limit.
This is the primary new event that drove the stock higher in July.
Strong backlog and CRDMO model A backlog of 66.43bn yuan, up 25.2%, signals future revenue growth. The CRDMO model, which integrates research, development, and manufacturing, continues to underpin the company's competitive advantage.
This supports the growth narrative and investor confidence.
US court blocks Pentagon label A US court injunction blocked the Pentagon's 'Chinese military company' designation, easing client fears about doing business with WuXi. This removes a key overhang on the stock.
This regulatory relief is a new positive catalyst for the stock.
Selloff and legal uncertainty A mid-July selloff saw CRO stocks limit-down and WuXi fall over 6%, showing sensitivity to market sentiment. The injunction is only preliminary; the lawsuit continues, and an adverse final ruling could still damage its US business.
This highlights the real counterweight and risks that remain.

Latest24 Jun – 13 Aug 2026

▲2▼1

WuXi AppTec wins injunction against Pentagon listing, sector rally continues

Court injunction blocks Pentagon blacklisting A US court granted WuXi AppTec a preliminary injunction, stopping the Pentagon from enforcing its 'Chinese military company' label during the lawsuit. This removes an immediate threat that could have scared off US clients and investors, lifting the stock.
This is the key new legal development that directly reduces regulatory risk for the company.
Sector-wide pharma rally gains steam Since WuXi AppTec's strong interim report on August 3, the whole pharmaceutical sector has climbed, with many stocks hitting daily limit-up. Analysts say this rally may last longer than past ones, pulling WuXi AppTec higher with the group.
Shows the broader market momentum that is lifting WuXi AppTec's price alongside peers.
Legal win is only temporary, final ruling pending The injunction is not a final judgment; the lawsuit continues and the Pentagon could still prevail. If the blacklisting is upheld later, it could hurt WuXi AppTec's US business and reputation, so the risk is not fully gone.
Provides the necessary counterweight: the legal threat is paused, not resolved.

17 Jul – 7 Aug 2026

▲3▼1

WuXi AppTec surges on blowout H1 results and raised 2026 guidance

H1 profit tops 10bn yuan for first time, guidance raised WuXi AppTec's first-half revenue rose 38.9% to 28.9bn yuan and net profit rose 29.4% to 11.08bn yuan, beating 10bn for the first time in a half. It raised full-year 2026 revenue guidance to 58.5-60.5bn yuan from 51.3-53bn, lifting the stock to limit-up.
This is the core new event that directly re-rated the stock and drove the sector rally.
Order backlog and CRDMO model underpin growth Continuing-operations backlog reached 66.43bn yuan at end-June, up 25.2% year-on-year. Analysts say the unique CRDMO model is gaining traction with more late-stage and commercial projects, and recovering global pharma R&D funding is reviving demand for outsourcing.
It explains the durable demand behind the raised guidance, not just a one-off earnings beat.
Sector-wide CRO rally amplifies the move The A-share CRO sector jumped over 7% on August 7, with 15 stocks up more than 10%. Six of eight CRO firms reporting so far showed double-digit profit growth. WuXi AppTec's results and guidance are the main catalyst pulling the whole group higher.
Shows the stock's rise is part of a broad sector re-rating, adding momentum beyond company-specific news.
Earlier July selloff shows sector fragility On July 17, CRO concept stocks hit limit-down and WuXi AppTec fell over 6% amid a broad A-share slump. This reminds investors that the stock remains sensitive to market-wide risk-off moves and sector sentiment swings, even with strong fundamentals.
Provides the counterweight: the stock is not immune to broad market and sector pullbacks.